SMARCE1 and breast carcinoma: By analyzing the expression data of 3554 breast tumor samples collected by an online Kaplan-Meier survival analysis tool [27], we found that higher expression of SMARCE1 or PTK2 is associated with shorter interval of relapse-free survival (RFS) of breast cancer patients (Fig. 11a).